Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0388)
| Name |
Isothiocyanate-containing hybrid AR antagonist 13
|
||||
|---|---|---|---|---|---|
| Drug Type |
Small molecule
|
||||
Full List of Ferroptosis Target Related to This Drug
Heme oxygenase 1 (HMOX1)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Driver/Suppressor | |||
| Responsed Disease | Prostate cancer | ICD-11: 2C82 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Glutathione metabolism | hsa00480 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | VCaP cells | Prostate carcinoma | Homo sapiens | CVCL_2235 |
| LNCaP cells | Prostate carcinoma | Homo sapiens | CVCL_0395 | |
| LNCaP C4-2 cells | Prostate carcinoma | Homo sapiens | CVCL_4782 | |
| 22Rv1 cells | Prostate carcinoma | Homo sapiens | CVCL_1045 | |
| RWPE-1 cells | Normal | Homo sapiens | CVCL_3791 | |
| MDA-kb2 cells | Breast adenocarcinoma | Homo sapiens | CVCL_6421 | |
| Response regulation | ITC-ARi 13 and buthionine sulfoximine (BSO) cooperatively downregulate AR and induce ferroptosis likely through increasing the accessibility of 13/12b to cellular targets, escalating free intracellular ferrous iron and attenuating GSH-centered cellular defense and adaptation. Further studies on the combination of ITC-ARi and GSH synthesis inhibitor could result in a new modality against castration-resistant prostate cancer (CRPC). Collectively, the combination of ITC-ARi 13 and BSO reveals a pro-ferroptotic role of Nrf2 through upregulating HO-1 under GSH-deficient conditions. | |||